Endogenous candida endophthalmitis in South Taiwan: A 10-year retrospective study  by Wang, Shih-Hao et al.
lable at ScienceDirect
Taiwan Journal of Ophthalmology 3 (2013) 146e150Contents lists avaiTaiwan Journal of Ophthalmology
journal homepage: www.e-t jo.comOriginal articleEndogenous candida endophthalmitis in South Taiwan: A 10-year
retrospective study
Shih-Hao Wang, Jong-Jer Lee, Yung-Jen Chen, Hsi-Kung Kuo*
Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwana r t i c l e i n f o
Article history:
Received 21 March 2013
Received in revised form
24 September 2013
Accepted 1 October 2013
Available online 16 November 2013
Keywords:
antifungal
endogenous candida endophthalmitis
visual acuity
vitrectomyThe authors have no conﬂicts of interest relevant to
* Corresponding author. Department of Ophthalmo
Memorial Hospital and Chang Gung University Colle
Ta-Pei Road, Niao-Sung District, Kaohsiung, Taiwan.
E-mail address: oyster@adm.cgmh.org.tw (H.-K. K
2211-5056/$ e see front matter Copyright  2013, Th
http://dx.doi.org/10.1016/j.tjo.2013.10.002a b s t r a c t
Purpose: To investigate the clinical manifestations and the results of the management of endogenous
candida endophthalmitis (ECE) at our hospital.
Methods: This study was a retrospective chart review conducted between September 2002 and
September 2012.
Results: Our study included 24 eyes of 14 patients. The culture results revealed Candida albicans in 11 cases
and Candida tropicalis in three cases. Diabetesmellitus, cancer, and intravenous catheter implantationwere
themost important risk factors for ECE. A systemic antifungal agent combinedwith intravitreal injection or
vitrectomy was our method for treating these cases and the complications. The outcomes were generally
poor, with a ﬁnal visual acuity (VA) of better than 0.1 in 10 cases, counting ﬁnger to 0.1 in six cases, light
perception to hand motion in six cases, and no light perception in two cases.
Conclusion: Unsatisfactory visual outcome in ECE is related to poor initial VA and complications. Early
diagnosis and prompt treatment are necessary for these patients.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Fungal endophthalmitis, which is a vision-threatening condi-
tion, may be either exogenous or endogenous. Exogenous infections
are usually secondary to trauma or surgery; endogenous fungal
endophthalmitis (EFE) represents intraocular dissemination of a
systemic fungal infection, and endogenous candida endoph-
thalmitis (ECE) is the most common form of EFE.1
Candida species exist as normal ﬂora on the human skin, res-
piratory tract, gastrointestinal tract, and genitourinary system, and
their growth is normally limited by the human immune system.
Candida albicans is responsible for the majority of candidemia cases
among the Candida species, but an increasing incidence of in-
fections caused by non-albicans Candida species (NAC) has been
noted.2e4 Fungi usually ﬁrst seed the highly vascular choroid and
subsequently move through the retina into the vitreous humor.5
The occurrence of ECE in patients with candidemia ranges from
9% to 45% in the published literature.6 Typical presentations of ECEthis article.
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e Ophthalmologic Society of Taiware eye pain, increased ﬂoaters, and blurred vision. The risk factors
include intravenous drug abuse, hyperalimentation, long-term us-
age of indwelling catheters, long-term antibiotic treatment, he-
modialysis, a recent history of gastrointestinal surgery, and
debilitating diseases such as diabetes mellitus or systemic immu-
nosuppression.5 Rare cases were reported in healthy immuno-
competent individuals.7,8
The prognosis following ECE depends on the extent of intraoc-
ular involvement and the timing and mode of interventions. Some
patients have poor visual outcome even after the treatment.
Prompt therapy following an early diagnosis helps reduce signiﬁ-
cant visual loss in ECE. The purpose of our study was to investigate
the clinical manifestations and the results of the management of
ECE at our hospital.
2. Methods
After obtaining Institutional Review Board (IRB) approval, we
retrospectively reviewed the medical records of 14 patients diag-
nosed with ECE at Kaohsiung Chang Gung Memorial Hospital be-
tween September 2002 and September 2012. Patients were eligible
if they met both criteria: (1) the typical appearance of ECE such as
irregular, ﬂuffy, yellow-white, or gray-white deep retinal lesions,
which are frequently accompanied by vitreous haze; and (2)
conﬁrmed positivity for candidemia-associated ECE from culturesan. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient characteristics of the study population.
Case no. Age (y) Sex Eye Initial VA Associated systemic
disease and conditions
Culture result Systemic treatment Intravitreal injection
of amphotericin B
(injection numbers)
Complications or management Final visual
outcome
1 53 M OD LP Type 2 DM
Hepatitis B
Candida albicans Fluconazole Yes
(3)
1. RD, PVR grade D2/VT, SB, silicone
oil tamponade (OD)
2. Persistent eye pain and no visual
function/evisceration (OD)
NLP
OS 0.05 Yes
(2)
No obvious complications during
follow-up (OS)
0.3
2 68 M OS CF Heart transplantation
Port-A implant
Candida albicans Caspofungin No RD with CD/VT, SB, silicone oil
tamponade (OS)
HM
3 40 F OD 0.01 Breast cancer
Port-A implant
Candida albicans Amphotericin B Yes
(1)
No obvious complications during
follow-up (OD)
0.03
OS CF Yes
(2)
RD with CD/VT, SB, gas tamponade
(OS)
0.01
4 59 F OD 0.03 Type 2 DM
Recurrent stroke
Candida albicans Fluconazole Yes
(1)
No obvious complications during
follow-up (OD)
0.03
OS 0.01 Yes
(2)
Dense epiretinal membrane with
tractional RD/VT, silicone oil
tamponade (OS)
CF
5 43 F OD 0.01 Type 2 DM
Hepatitis C
Candida albicans Fluconazole No Macular pucker (OD > OS)/VT (OU) 0.1
OS 0.1 No 1.0
6 48 F OD 0.02 Type 2 DM Candida albicans Amphotericin B
Fluconazole
Yes
(1)
Macular pucker (OU)/VT, gas
tamponade (OD)
0.01
OS 0.03 No 0.01
7 59 M OD CF Type 2 DM
Hepatitis C
Candida albicans Fluconazole No No obvious complications during
follow-up (OD)
0.1
OS CF Yes
(2)
Macular pucker/VT (OS) HM
8 31 M OD 0.1 Precursor T-cell
lymphoblastic lymphoma
Port-A implant
Hepatitis B
Candida tropicalis Caspofungin
Fluconazole
Yes
(1)
Macular CNV with hemorrhage
(OS > OD)/intravitreal injection
of Bevacizumab (Avastin) (OS)
0.2
OS 0.6 No 0.7
9 57 M OS CF Tongue cancer
Hepatitis C with liver
cirrhosis
Yeast-like
(Pathology report:
candidiasis)
Fluconazole No 1. Severe vitritis/VT (OS)
2. Corneal melting and
perforation/evisceration (OS)
NLP
10 73 F OD CF Type 2 DM
Hepatitis C
Candida albicans Fluconazole Yes
(1)
Severe vitritis and vitreous
opacity/VT (OD)
LP
11 78 M OD HM Type 2 DM Candida albicans Fluconazole
Micafungin
No Persistent vitritis and vitreous
opacity/observation (OU)
HM
12 82 M
OS CF
Intravenous catheter Candida albicans Anidulafungin
No
Corneal and vitreous
opacity/observation (OS)
HM
OS HM Yes
(1)
HM
13 45 F OD 0.4 Breast cancer
Port-A implant
Candida tropicalis Fluconazole
Caspofungin
Micafungin
Voriconazole
No No obvious complications
during follow-up (OU)
0.7
OS 0.5 No 0.6
14 60 M OD 0.5 Type 2 DM
Hepatitis B
AML
Intravenous catheter
Port-A implant
Candida tropicalis Micafungin
Voriconazole
Yes
(1)
No obvious complications
during follow-up (OU)
0.2
OS 0.8 Yes
(1)
0.4
AML ¼ acute myeloid leukemia; CD ¼ choroidal detachment; CF ¼ counting ﬁnger; CNV ¼ choroidal neovascularization; DM ¼ diabetic diabetes mellitus; F ¼ female; HM ¼ hand motion; LP ¼ light perception; M ¼ male;
NLP ¼ no light perception; OD ¼ right eye; OS ¼ left eye; OU ¼ bilateral eyes; PVR ¼ proliferative vitreoretinopathy; RD ¼ retinal detachment; SB ¼ scleral buckle; VA ¼ visual acuity; VT ¼ vitrectomy.
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S.-H. Wang et al. / Taiwan Journal of Ophthalmology 3 (2013) 146e150148obtained from the vitreous, blood, urine, or cerebrospinal ﬂuid
(CSF). Patients with a history of severe ocular trauma, intraocular
inﬂammation, or intraocular surgery were excluded. The collected
information included age, gender, the initial visual acuity (VA) at
the time of the ECE attack, systemic disorders, associated risk fac-
tors, clinical manifestations, culture results, responses to systemic
or local treatment, complications, and the ﬁnal visual outcome.Fig. 2. Case 9. Severe inﬂammation with total corneal opacity, corneal melting,
perforation, and severe conjunctival congestion are apparent in the patient’s left eye
(OS).3. Results
In our study, 24 eyes of 14 patients aged 31e82 years
[mean  standard deviation (SD), 56.86  14.84 years] were diag-
nosed with ECE. The participants included eight men and six
women (Table 1). Involvement of both or one eye was noted in 10
patients (71.4%) and in four patients (28.6%), respectively. Associ-
ated underlying systemic diseases were present as follows: eight
patients (57.1%) had type 2 diabetes mellitus, six patients (42.9%)
had indwelling intravenous catheters (including port-A implants),
ﬁve patients (35.7%) had cancer, one patient (7.1%) was undergoing
systemic immunosuppressive therapy after heart transplantation,
and one patient (7.1%) had chronic hepatitis with liver cirrhosis.
According to the cultures obtained from the blood or vitreous
humor, 10 cases (71.4%) involved C. albicans, which was the most
common pathogen found in our study, followed by three cases
(23.1%) that involved Candida tropicalis. C. albicans were also found
in the urine cultures of three patients with urosepsis. We also
included one case in our study (Case 9) in which the pathology
report of the vitrectomy specimen showed candidiasis and the
culture yielded yeast-like pathogens.
All patients received treatment with systemic antifungal agents
such as amphotericin B, ﬂuconazole, voriconazole, caspofungin,
and micafungin. Auxiliary intravitreal injection of amphotericin B
(5 mg/0.1 mL) was given to 13 of 24 eyes (54.2%).
The important complications included retinal detachment,
macular pucker, choroidal neovascularization (CNV), persistentFig. 1. Case 8. (A) Macular ﬁbrosis and subretinal hemorrhage (arrow) at the nasal side of
massive subretinal hemorrhage at the temporal side of the fovea are apparent in the left
intravitreal bevacizumab injections during the 4th month of follow-up.vitritis, corneal melting, and corneal perforation. Retinal detach-
ment was found in four eyes (16.7%; Cases 1e4), and this was
combinedwith choroidal detachment in two eyes. In one of the two
eyes with combined retinal and choroidal detachment, four-
quadrant retinal folds with retinal stiffness and a narrow funnel
shape were observed in surgery, resulting in a classiﬁcation as a
grade D2 proliferative vitreoretinopathy (PVR) according to the
1983 Retina Society Terminology Committee (Case 1).9 All four eyes
with retinal detachment were treated with vitrectomy and silicone
oil tamponade, and three eyes were also treated with implantation
with an encircling scleral buckle. During the postoperative follow-
up period, three of four eyes had a well-attached retina and the
ﬁnal visual outcomes were handmotion, counting ﬁngers, and 0.01.the parafoveal area are apparent in the right eye (OD). (B) Mild macular ﬁbrosis and
eye (OS). (C) In the left eye (OS), the subretinal hemorrhage disappeared after two
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underwent evisceration because of persistent eye pain.
During the follow-up period, macular pucker occurred in ﬁve
eyes (20.8%), four of which underwent vitrectomy and epiretinal
membrane peeling (Cases 5e7). Among these cases, the ﬁnal vision
in one eye was 1.0 (Case 5), whereas the ﬁnal vision in others
ranged between hand motion and 0.1. Macular CNV and macular
hemorrhage occurred in both eyes of one patient 16 months after
regression of ECE (Case 8; Fig. 1A and B). He received two intra-
vitreal injections of Bevacizumab (Avastin; 1.25 mg/0.05 mL) in his
left eye because of foveal involvement. The CNV of his left eye
regressed after the treatment (Fig. 1C). The ﬁnal VA of his left eye
was 0.7, but the VA of his right eye was 0.2 because of macular
ﬁbrosis.
Among the 24 eyes included in this study, the ﬁnal VAwas better
than 0.1 in 10 eyes (41.7%), counting ﬁnger to 0.1 in six cases (25.0%),
light perception to hand motion in six cases (25.0%), and no light
perception in two cases (8.3%). The two eyes with a ﬁnal VA of no
light perception underwent evisceration because of persistent eye
pain in one case (Case 1) and persistent severe inﬂammation
associated with corneal melting and perforation in the other case
(Case 9; Fig. 2).
In our study, all of the seven eyes with an initial VA better than
0.1 had a ﬁnal VA better than 0.1 (100%). By contrast, only three of
17 eyes (17.6%) with an initial VA worse than 0.1 had a ﬁnal VA
better than 0.1. (p ¼ 0.0003). Besides, four eyes (Cases 1e4) that
were complicated with retinal detachment underwent surgery for
treatment, but a ﬁnal VA better than 0.1 could not be achieved in
any eye. However, this association was not signiﬁcant when
compared to the eyes without retinal detachment (p ¼ 0.1140).
4. Discussion
In our study, C. albicans (76.9%) was the Candida species that
most frequently caused ECE, followed by C. tropicalis (23.1%). These
results are similar to those of the study of Essman et al,10 who
identiﬁed 17 (85%) Candida species and three (15%) Aspergillus
species in 20 culture-proven EFE cases; in the Candida species
group, 12/17 (70.6%) cases were C. albicans and 5/17 (29.4%) cases
were C. tropicalis. A notable ﬁnding in our study was that the pa-
tients infected by C. tropicalis all had better visual outcomes than
those infected by C. albicans, suggesting that C. tropicalis is less
virulent than the C. albicans sp. that causes endogenous endoph-
thalmitis. However, further large randomized controlled clinical
trials are required to determine the morbidity and toxicity of these
pathogens.
Diabetes mellitus (57.1%) was the most common ECE risk factor,
followed by long-term usage of indwelling catheters and cancer. In
a study performed by Takebayashi et al11 in Japan, 43 of 58 patients
(74.1%) with EFE had cancer and only one case had diabetes mel-
litus, which was signiﬁcantly different from the ﬁnding in our
study. These variationsmay result fromdifferences in dietary habits
and ethnicity between Taiwanese and Japanese participants as well
as the limited number of cases. The study performed by Essman
et al10 showed that long-term intravenous catheter use (67%) was
the major predisposing factor of EFE, and most of the patients had
more than two risk factors.
We initially used systemic antifungal agents, such as ﬂuconazole
or amphotericin B, to treat candida chorioretinitis in our cases.
According to the guideline from the Infectious Diseases Society of
America (IDSA) in 2009, ﬂuconazole (a loading dose of 800 mg
(12 mg/kg), followed by 400 mg (6 mg/kg) daily) or an echino-
candin (such as caspofungin, micafungin, or anidulafungin) is rec-
ommended as the initial therapy for most non-neutropenic
patients with candidemia. However, amphotericin B deoxycholate(0.5e1.0 mg/kg daily) or a lipid formulation of amphotericin B (3e
5 mg/kg daily) is an alternative if intolerance or limited availability
of other antifungals is an issue. For cases complicated with ECE,
amphotericin B (0.7e1 mg/kg) with ﬂucytosine (25 mg/kg, 4 times
a day) or ﬂuconazole (6e12 mg/kg daily) is recommended.12
An intravitreal injection of amphotericin B was administered if
active vitreous inﬂammation, macular involvement, or evidence
that the patient was refractory to current medical therapy was
observed. We used a dosage of 5 mg/0.1 mL of amphotericin B for
intravitreal injection because previous studies demonstrated that
this dose is generally well tolerated.13 In addition, the intravitreal
injection of voriconazole can be used as a newer treatment option
in fungal endophthalmitis. Chang et al14 reported a case with
bilateral ECE successfully treated with multiple intravitreal in-
jections of voriconazole combined with systemic treatment. Intra-
vitreal injections of voriconazole (100 mg/0.1 mL) were
administered immediately upon the diagnosis of ECE, 3 days after
the diagnosis when the systemic condition had stabilized, and as
weekly injections for 6weeks thereafter. The retinal lesions showed
regression and the VA improved.
Vitrectomy was considered if the patient had a poor response to
the above treatments. However, the effect of vitrectomy remains
controversial, and this procedure may be difﬁcult to perform in an
infected eye. Takebayashi et al11 recommended vitreous surgery if
medical treatments were ineffective. They reported that 29 eyes of
21 patients who received vitreous surgery still had unsatisfactory
visual prognoses, with 16 of 29 eyes (55.2%) having a ﬁnal vision of
less than 0.1 and six eyes (20.7%) having no light perception after
the surgery. The poor visual prognosis was probably because the
cases were so severe that medical treatment had little effect or was
associated with severe complications such as retinal detachment,
which independently leads to worse vision. However, in the study
performed by Essman et al,10 only three of 11 patients (27.2%) with
C. albicans-associated EFE had a ﬁnal VA of less than 0.1 after
receiving vitreous surgery. In our study, 10 eyes received vitrec-
tomy, including four with retinal detachment, four with macular
pucker, and two with severe vitritis and persistent vitreous opaci-
ties. The ﬁnal visionwasworse than 0.1 in nine eyes (9/10, 90%). The
differences among these studies may be associated with the vari-
ations in patient selection, surgical indications, and timing.
Tanaka et al15 divided EFE into four stages: Stage I, chorioretinal
changes without extension into the vitreous cavity; Stage II, a
fungal mass penetrating through the inner limiting membrane and
budding into the vitreous cavity; Stage III, vitreous opacity resulting
in a blurred fundus; and Stage IV, Stage III plus the complications of
retinal detachment. Takebayashi et al,11 who described the associ-
ation between the severity of EFE and the interval between the
presence of ocular symptoms and the ophthalmologist’s initial visit,
found that those with an interval of more than 15 days had a higher
rate of occurrence of Stage III or Stage IV EFE at the initial visit. The
rate at which patients developed advanced-stage EFE increased as
the interval prior to the EFE diagnosis increased, and this associa-
tion was statistically signiﬁcant. He also described the association
between the severity of EFE and visual prognosis, and reported that
all patients with an initial Stage I EFE had a ﬁnal VA better than 0.1
and 40%were better than 0.6. However, six eyes with initial Stage IV
EFE had no light perception.11
Poor visual outcome was also related to poor initial VA and
centrally located fungal lesions in Sallam’s study.16 These authors
included 44 eyes from 36 patients diagnosed with ECE and found
that a poor initial VA and a central retinal lesion were the most
important risk factors leading to visual loss (VA < 0.5) and severe
visual loss (VA < 0.1). Therefore, a satisfactory visual outcome re-
quires an early diagnosis and prompt treatment when indicated. In
our study, we also found that 100% eyes with an initial VA better
S.-H. Wang et al. / Taiwan Journal of Ophthalmology 3 (2013) 146e150150than 0.1 had a ﬁnal VA better than 0.1, and only 17.6% eyes with an
initial VAworse than 0.1 had a ﬁnal VA better than 0.1 (p¼ 0.0003).
We observed a tendency for the eyes with a better initial VA to have
a better visual outcome in general, possibly, because they were
diagnosed at an early stage and were able to undergo prompt
treatment to prevent the occurrence of associated complications.
Moreover, the possible inﬂuencing factors leading to poor ﬁnal
visual outcomes were usually related to ECE-associated complica-
tions, especially retinal detachment. However, this association was
not signiﬁcant (p ¼ 0.1140) because the number of cases was too
small.
Macular CNV is usually caused by inﬂammatory or infectious
diseases of the posterior segment. Ocular candidiasis-induced
macular CNV was ﬁrst reported in 1987.17 Treatment modalities
that have been studied for macular CNV include laser photocoag-
ulation, photodynamic therapy, the use of anti-vascular endothelial
growth factor (VEGF) agents, and surgical intervention to remove
the neovascular membrane.18e20 Currently, anti-VEGF agents are
commonly used because their use is supported by many large
randomized studies for the treatment of conditions such as wet-
type age-related macular degeneration, diabetic macular edema,
or retinopathy of prematurity.21e23 Furthermore, studies have
demonstrated that the use of anti-VEGF agents for the treatment of
macular CNV secondary to infectious or inﬂammatory disorders
such as myopic CNV,24 presumed ocular histoplasmosis syndrome
(POHS),25 VogteKoyanagieHarada (VKH) disease,26 and uveitic
CNV27 can stabilize the disease and improve the VA. In our study,
we also used intravitreal injection of anti-VEGF for macular CNV,
which resulted in favorable visual outcome.
The major limitations of our study were the small sample size
and the retrospective review of medical records, which limited our
ability to study the various factors that may have inﬂuenced the
visual outcome. In addition, the timing and mode of treatment
slightly differed according to the physician, leading to varied
results.
In summary, we found that some patients with ECE had un-
satisfactory visual outcome even after treatment. The most
important risk factors included diabetes mellitus, cancer, and
intravenous catheter implantation, and a poor initial VA was an
important inﬂuencing factor for ﬁnal outcome. Early diagnosis and
prompt treatment are necessary for these patients in order to
provide better ﬁnal vision.
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